share_log

10-K: FY2024 Annual Report

SEC ·  Mar 26 21:18

Summary by Futu AI

BioCardia reported financial results for fiscal year 2024, with net loss narrowing to $7.9 million from $11.6 million in 2023. Revenue decreased to $58,000 from $477,000 year-over-year, while operating expenses reduced significantly to $8.1 million from $12.1 million, driven by lower research and development costs following completion of the CardiAMP Cell Therapy Heart Failure Trial.The company completed enrollment in its pivotal CardiAMP Cell Therapy Heart Failure Trial, with principal results scheduled for presentation at the ACC Scientific Sessions on March 30, 2025. BioCardia also initiated the CardiAMP Heart Failure II Trial targeting 250 patients and advanced its CardiAMP Chronic Myocardial Ischemia Trial. The low-dose cohort of the CardiALLO allogeneic cell therapy trial was completed with no safety issues reported.As of December 31, 2024, BioCardia had cash and equivalents of $2.4 million, which management believes will fund operations through May 2025. The company raised $9.3 million in 2024 through equity offerings, including a $7.2 million registered offering in September. Management indicated additional funding will be required to advance clinical programs and continue operations beyond May 2025.
BioCardia reported financial results for fiscal year 2024, with net loss narrowing to $7.9 million from $11.6 million in 2023. Revenue decreased to $58,000 from $477,000 year-over-year, while operating expenses reduced significantly to $8.1 million from $12.1 million, driven by lower research and development costs following completion of the CardiAMP Cell Therapy Heart Failure Trial.The company completed enrollment in its pivotal CardiAMP Cell Therapy Heart Failure Trial, with principal results scheduled for presentation at the ACC Scientific Sessions on March 30, 2025. BioCardia also initiated the CardiAMP Heart Failure II Trial targeting 250 patients and advanced its CardiAMP Chronic Myocardial Ischemia Trial. The low-dose cohort of the CardiALLO allogeneic cell therapy trial was completed with no safety issues reported.As of December 31, 2024, BioCardia had cash and equivalents of $2.4 million, which management believes will fund operations through May 2025. The company raised $9.3 million in 2024 through equity offerings, including a $7.2 million registered offering in September. Management indicated additional funding will be required to advance clinical programs and continue operations beyond May 2025.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 248

Recommended